EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum

Alexandra N Trelle, Christina B Young, Hillary Vossler, Javier Ramos Benitez, Karly A Cody, Justin H Mendiola, Michelle S Swarovski, Yann Le Guen, Igor Feinstein, Robert R Butler, Divya Channappa, America Romero und 23 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Alexandra N Trelle und 34 weiteren Autor:innen. Beteiligte Einrichtung: Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Cognitive Dysfunction, Peptide Fragments. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Centralized Repository Alzheimer's Disease and Related Dementias.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS We evaluated fully‐automated Lumipulse plasma Aβ 42 /Aβ 40 immunoassays for detecting cerebral Aβ in 457 clinically unimpaired (CU) and clinically impaired (CI) Stanford Alzheimer's Disease Research Center (Stanford ADRC) participants and 186 CU in the Stanford Aging and Memory Study (SAMS). Longitudinal change in ADRC plasma Aβ 42 /Aβ 40 and cognition and cross‐sectional associations with SAMS memory and tau positron emission tomography (PET) were examined. RESULTS Plasma Aβ 42 /Aβ 40 exhibited high performance in detecting amyloid positivity defined by PET (area under the curve [AUC]: 0.885, 95% confidence interval [CI]: 0.816–0.955). Once abnomal, plasma Aβ 42 /Aβ 40 remained low and predicted cognitive decline in both CU and CI individuals. Among SAMS CU, plasma Aβ 42 /Aβ 40 was associated with poorer hippocampal‐dependent memory and elevated tau accumulation. DISCUSSION Lumipulse plasma Aβ 42 /Aβ 40 is a scalable assay for detection of cerebral Aβ and prediction of risk for cognitive decline across the AD continuum. Highlights Lumipulse plasma amyloid beta (Aβ) 42 /Aβ 40 exhibited high accuracy in detecting amyloid positivity. Plasma amyloid‐positive (Aβ+) individuals exhibited stability of Aβ 42 /Aβ 40 over time. Plasma Aβ 42 /Aβ 40 predicted future cognitive decline across the Alzheimer's disease (AD) spectrum. Plasma Aβ 42 /Aβ 40 was sensitive to memory and tau burden in clinically unimpaired older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseCognitive DysfunctionPeptide FragmentsBrainHumansMaleFemaleAgedPositron-Emission TomographyBiomarkersCross-Sectional StudiesLongitudinal Studiestau ProteinsAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's diseaseblood biomarkerscognitionplasma Aβ42/Aβ40

Substanzen

Amyloid beta-PeptidesPeptide FragmentsBiomarkerstau Proteinsamyloid beta-protein (1-42)amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Quantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, California, USA.
  • Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, California, USA.
  • Neurology, Yale University, New Haven, Connecticut, USA.
  • Biomedical Data Science and Statistics, Stanford University, Stanford, California, USA.
  • Pharma Research and Early Development, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Centralized Repository Alzheimer's Disease and Related Dementias
  • Scully Research Initiative
  • Stanford PHIND Institute
  • Jean Perkins Foundation
  • Good Planet Foundation
  • NCATS NIH HHS

Zitieren

APA

Trelle, A. N., Young, C. B., Vossler, H., Ramos Benitez, J., Cody, K. A., Mendiola, J. H., Swarovski, M. S., Guen, Y. L., Feinstein, I., Butler, R. R., Channappa, D., Romero, A., Park, J., Shahid-Besanti, M., Corso, N. K., Chau, K., Smith, A. N., Skylar-Scott, I., Yutsis, M. V., …, & Wilson, E. N. (2025). Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14442

Vancouver

Trelle AN, Young CB, Vossler H, Ramos Benitez J, Cody KA, Mendiola JH, et al. Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14442

BibTeX
@article{Trelle2025,
  author = {Trelle, Alexandra N and Young, Christina B and Vossler, Hillary and Ramos Benitez, Javier and Cody, Karly A and Mendiola, Justin H and Swarovski, Michelle S and Guen, Yann Le and Feinstein, Igor and Butler, Robert R and Channappa, Divya and Romero, America and Park, Jennifer and Shahid-Besanti, Marian and Corso, Nicole K and Chau, Kelly and Smith, Amanda N and Skylar-Scott, Irina and Yutsis, Maya V and Fredericks, Carolyn A and Tian, Lu and Younes, Kyan and Kerchner, Geoffrey A and Deutsch, Gayle K and Davidzon, Guido A and Sha, Sharon J and Henderson, Victor W and Longo, Frank M and Greicius, Michael D and Wyss-Coray, Tony and Andreasson, Katrin I and Poston, Kathleen L and Wagner, Anthony D and Mormino, Elizabeth C and Wilson, Edward N},
  title = {Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14442}
}
Kostenlos starten →